Your browser doesn't support javascript.
loading
Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study.
Hiratsuka, Yusuke; Tagami, Keita; Inoue, Akira; Sato, Mamiko; Matsuda, Yasufumi; Kosugi, Kazuhiro; Kubo, Emi; Natsume, Maika; Ishiki, Hiroto; Arakawa, Sayaka; Shimizu, Masaki; Yokomichi, Naosuke; Chiu, Shih-Wei; Shimoda, Mayu; Hirayama, Hideyuki; Nishijima, Kaoru; Ouchi, Kota; Shimoi, Tatsunori; Shigeno, Tomoko; Yamaguchi, Takuhiro; Miyashita, Mitsunori; Morita, Tatsuya; Satomi, Eriko.
Afiliación
  • Hiratsuka Y; Department of Palliative Medicine, Takeda General Hospital, Aizu Wakamatsu, Japan. hiratsuka.med.t@gmail.com.
  • Tagami K; Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. hiratsuka.med.t@gmail.com.
  • Inoue A; Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Sato M; Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Matsuda Y; Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Kosugi K; Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Kubo E; Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan.
  • Natsume M; Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan.
  • Ishiki H; Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan.
  • Arakawa S; Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Shimizu M; Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Yokomichi N; Department of Palliative Care, Kyoto-Katsura Hospital, Kyoto, Japan.
  • Chiu SW; Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
  • Shimoda M; Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Hirayama H; Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Nishijima K; Department of Palliative Nursing, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Ouchi K; Department of Palliative Care, Kyowakai Medical Corporation, Daini Kyoritsu Hospital, Kawanishi, Japan.
  • Shimoi T; Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
  • Shigeno T; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yamaguchi T; Department of Palliative Nursing, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Miyashita M; Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Morita T; Department of Palliative Nursing, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Satomi E; Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Support Care Cancer ; 31(12): 632, 2023 Oct 16.
Article en En | MEDLINE | ID: mdl-37843639
PURPOSE: Although opioids have been shown to be effective for cancer pain, opioid-induced adverse events (AEs) are common. To date, little is known about the differences in risks of AEs by opioid type. This study was performed to compare the prevalence of AEs across opioids commonly used for analgesic treatment in Japan. METHODS: This study was conducted as a preplanned secondary analysis of a multicenter prospective longitudinal study of inpatients with cancer pain who received specialized palliative care for cancer pain relief. We assessed daily AEs until termination of follow-up. We rated the severity of AEs based on the Common Terminology Criteria for Adverse Events version 5.0. We computed adjusted odds ratios for each AE (constipation, nausea and vomiting, delirium, and drowsiness) with the following variables: opioid, age, sex, renal dysfunction, and primary cancer site. RESULTS: In total, 465 patients were analyzed. Based on the descriptive analysis, the top four most commonly used opioids were included in the analysis: oxycodone, hydromorphone, fentanyl, and tramadol. With respect to the prevalence of AEs among all analyzed patients, delirium (n = 25, 6.3%) was the most frequent, followed by drowsiness (n = 21, 5.3%), nausea and vomiting (n = 19, 4.8%), and constipation (n = 28, 4.6%). The multivariate logistic analysis showed that no single opioid was identified as a statistically significant independent predictor of any AE. CONCLUSION: There was no significant difference in the prevalence of AEs among oxycodone, fentanyl, hydromorphone, and tramadol, which are commonly used for analgesic treatment in Japan.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tramadol / Delirio / Dolor en Cáncer Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tramadol / Delirio / Dolor en Cáncer Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania